Drug tested for Hard-to-Treat stomach tumors shows limited promise
NCT ID NCT00756509
Summary
This study tested whether the drug nilotinib could help control advanced gastrointestinal stromal tumors (GIST) in adults who had not yet received treatment for their metastatic disease. It enrolled 34 patients to take nilotinib daily and measured if their tumors shrank or stopped growing. The trial was stopped early because a larger study suggested nilotinib was unlikely to work better than the standard drug imatinib, though this smaller study continued to provide the drug to some patients already benefiting from it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Helsinki, FIN-00029, Finland
-
Novartis Investigative Site
Lyon, 69373, France
-
Novartis Investigative Site
Munich, Bavaria, 81377, Germany
-
Novartis Investigative Site
Bad Saarow, 15526, Germany
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Hanover, 30625, Germany
-
Novartis Investigative Site
Milan, MI, 20133, Italy
Conditions
Explore the condition pages connected to this study.